Krishnansu S. Tewari, MD
Professor
UC Irvine Medical Center
Dept. OB/GYN Division of Gynecologic Oncology
101 The City Drive
Bldg. 56
Orange,
CA
USA
92868
Biographical Sketch: I am the Director of Research in Gynecologic Oncology and the Principal Investigator of the Gynecologic Oncology Group at UC Irvine. Within the GOG I am the Study Chair for the Phase III randomized clinical trial GOG 240. I currently am the PI of an NCI-funded R21 grant to study surrogate markers of angiogenesis. I prepared the concept for this SGO 2013 abstract submission of the GOG 218 ancillary data study and conducted the data analysis and wrote the abstract.
Papers:
5
Correlation between surgeon's assessment of residual disease and findings on postoperative pre-treatment computed tomography scan in women with advanced stage ovarian cancer reported to have undergone optimal cytoreduction: an NRG Oncology/GOG study
24
Impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study
31
Full thickness Skin Graft for McIndoe Neovagina to Treat Vaginal Agenesis in Mayer-Rokitansky-Küster-Hauser Syndrome
57
Impact of treatment-induced neutropenia and thrombocytopenia on survival in patients with advanced ovarian cancer treated with chemotherapy plus bevacizumab: an NRG Oncology/Gynecologic Oncology Group ancillary data study
62
Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study
268
Primary debulking surgery and neo-adjuvant chemotherapy in the Medicare population: an analysis of cost of care
347
Microarray analysis of vascular endothelial growth factor (VEGF)-dependent angiogenic biomarkers in squamous cell carcinoma (SCCA) and adenocarcinoma (AC) of the cervix
348
Paving the road to personalized medicine in cervical cancer: theranostic biomarker evaluation in a 592-specimen library
355
Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study
Proof of concept for anti-angiogenesis therapy in recurrent and metastatic cervical cancer
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian